Dr. Thomas Lynch joined Bristol-Myers Squibb in March 2017 as Chief Scientific Officer to lead the Research & Development organization, bringing broad leadership experience, significant experience in drug development, and a deep understanding of the patient perspective as a treating oncologist. He previously served as a director on Bristol-Myer Squibb’s board from 2013-2017. Tom hasRead more..
Posts Tagged ‘Bristol Myers Squibb’
A groundbreaking new melanoma treatment is being rolled out to patients in the U.K., but may never reach those in Ireland. The National Pharmacoeconomics Centre (NCPE), an independent medicine cost advisory board, has recommended that the HSE does not make the Opdivo drug available through the public system due to uncertainty about its financial sustainability. Research has provenRead more..